Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors
By: Insiya B. Poonawalla, MS, PhD, Petir Abdal, PharmD, MBA, Mary Hayes, PharmD, BCPS, Isha John, PharmD, MBA, Monica Diaz, PharmD, RPh, BCPS, Suzanne Dixon, MPH, MS, RDN, and Andy Bowe, MPH
To compare health care resource utilization and costs in adults with type 2 diabetes newly initiating GLP-1 RA vs SGLT2i therapy.